Related Topics News -

     
 Detail   |   Print 
     
科倫博泰:中證監就公司H股全流通發出備案通知書
2026-03-30T  
《大行》招銀國際升科倫博泰生物目標價至507.11元 商業化啟航
2026-03-26T  
《大行》美銀證券升科倫博泰目標價至523.3元 上調至「買入」評級
2026-03-26T  
《大行》招銀國際升科倫博泰目標價至507.11元 評級「買入」
2026-03-25T  
《大行》里昂降科倫博泰生物目標價至500.7元 評級「跑贏大市」
2026-03-25T  
科倫博泰生物SKB103新藥臨床試驗申請獲國家藥監局批准
2026-03-24T  
《大行》高盛降科倫博泰目標價至526.49元 下調每股盈測
2026-03-24T  
《大行》瑞銀降科倫博泰目標價至578元 降盈測重申「買入」
2026-03-24T  
《業績》科倫博泰生物全年虧損擴至3.82億人幣
2026-03-23T  
科倫博泰蘆康沙妥珠單抗於2026年ELCC公布研究結果
2026-03-19T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.